Rivaroxaban for Intracardiac Thrombosis in the Pediatric Population

The Investigators will enroll all the consecutive pediatric patients (< 16 years old) treated with rivaroxaban (dosage based on patient's body weight - 0.9 mg/Kg/Day) due to intracardiac thrombosis (ICT) suspected by echocardiography and confirmed with cardiac computed tomography (CCT) or magnetic resonance (CMR) imaging. All the participants will be treated with enoxaparin for 7 days before the rivaroxaban implementation. The treatment will last for 3 months.

The participants will undergo monthly visits to check that the treatment is progressing correctly and that no major bleeding has occurred. Bleeding severity will be assessed utilizing the Bleeding Assessment Scale in Critically Ill Children (BASIC). CCT/CMR will be repeated to confirm the thrombosis resolution. After 3 months of treatment, they will repeat the radiological imaging investigation to verify the effective resolution of the thrombosis, or it will be continued for another 3 months if there is no resolution of the thrombosis.

Inclusion criteria

• Intracardiac thrombosis demonstration at echocardiography and CMR/CCT confirmation
• Given informed consent from the parents or tutors

Exclusion criteria

• < 38 weeks of gestational birth
• < 10 days of oral feeding and body weight
• < 2.6 Kg
• Any major or clinically relevant bleeding event or abnormal coagulation test results within 10 days prior to the enrollment for the whole population